Viracta Therapeutics - VIRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 277.36 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.12
▼ -0.13 (-5.78%)

This chart shows the closing price for VIRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Viracta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIRX

Analyst Price Target is $8.00
▲ +277.36% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Viracta Therapeutics in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 277.36% upside from the last price of $2.12.

This chart shows the closing price for VIRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Viracta Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2022Royal Bank of CanadaLower TargetOutperform$10.00 ➝ $8.00Low
5/12/2022HC WainwrightReiterated RatingBuyHigh
2/1/2022Royal Bank of CanadaInitiated CoverageOutperform$10.00High
11/14/2021SVB LeerinkReiterated RatingBuy$18.00Medium
10/7/2021HC WainwrightReiterated RatingBuy$35.00Low
8/15/2021SVB LeerinkReiterated RatingBuy$18.00High
7/26/2021HC WainwrightReiterated RatingBuy$35.00Medium
5/3/2021SVB LeerinkInitiated CoverageOutperform$18.00High
5/3/2021HC WainwrightInitiated CoverageBuy$35.00High
4/26/2021SVB LeerinkInitiated CoverageOutperformHigh
3/25/2021Evercore ISIInitiated CoverageOutperform$45.00Low
2/26/2021OppenheimerBoost TargetOutperform$12.00 ➝ $36.00Low
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Viracta Therapeutics logo
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Read More

Today's Range

Now: $2.12
Low: $2.02
High: $2.26

50 Day Range

MA: $3.51
Low: $2.12
High: $4.37

52 Week Range

Now: $2.12
Low: $1.82
High: $5.75

Volume

143,900 shs

Average Volume

212,178 shs

Market Capitalization

$80.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Viracta Therapeutics?

The following sell-side analysts have issued research reports on Viracta Therapeutics in the last year: HC Wainwright, and Royal Bank of Canada.
View the latest analyst ratings for VIRX.

What is the current price target for Viracta Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Viracta Therapeutics in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 277.4%. Royal Bank of Canada has the highest price target set, predicting VIRX will reach $8.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $8.00 for Viracta Therapeutics in the next year.
View the latest price targets for VIRX.

What is the current consensus analyst rating for Viracta Therapeutics?

Viracta Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VIRX will outperform the market and that investors should add to their positions of Viracta Therapeutics.
View the latest ratings for VIRX.

What other companies compete with Viracta Therapeutics?

How do I contact Viracta Therapeutics' investor relations team?

Viracta Therapeutics' physical mailing address is 2533 S. COAST HWY. 101 SUITE 210, CARDIFF CA, 92007. The company's listed phone number is (858) 400-8470 and its investor relations email address is [email protected] The official website for Viracta Therapeutics is www.viracta.com. Learn More about contacing Viracta Therapeutics investor relations.